I can extract side effects

A fast-acting antihypertensive drug!

Wei Kang stared at the prescription in front of him with burning eyes, and his heart was full of joy.

As we all know, hypertension is a common chronic disease in modern society and the most important risk factor for cardiovascular and cerebrovascular diseases.

As the age increases, the incidence of hypertension will gradually increase, and the incidence rate is very high for those over 40 years old.

The causes of high blood pressure are complex, long-term mental stress, unreasonable dietary structure, such as high-salt, low-potassium, high-fat diet, alcoholism, smoking, etc., can all lead to high blood pressure.

At present, the world's best-selling quick-acting antihypertensive drug is Huoluoxi developed by Pfizer. It has been on the market for more than two decades and is one of the most prescribed high blood pressure drugs in the world. It has been used more than 40 billion times worldwide.

Commonly used antihypertensive drugs mainly include sartan and dipine, and Huoluoxi is the representative of dipine.

Dipine antihypertensive drugs are fast and long-acting. It doesn’t matter if the patient occasionally misses a dose, but the load on the kidneys will be relatively large.

It is a calcium ion antagonist, which can inhibit the transmembrane entry of calcium ions into vascular smooth muscle and myocardium, thereby dilating blood vessels and lowering blood pressure.

Sartan antihypertensive drugs have fewer side effects, but they are metabolized faster, so patients cannot miss doses. Moreover, the rate of lowering blood pressure is slower than that of dipine drugs, and it is mainly used for long-term use to control blood pressure.

This is also an antagonist, acting on angiotensin receptors, which can block the vasoconstrictive effect of angiotensin, thereby dilating blood vessels and lowering blood pressure.

The targets of sartan-type antihypertensive drugs and pril-type antihypertensive drugs are similar, and each has its own advantages and disadvantages. However, the two generally cannot be used together at the same time, and doctors need to use them according to the specific conditions of the patient.

The new antihypertensive drug in front of Weikang is not the above common antihypertensive drugs, but it has a better antihypertensive effect.

Its drug principle is also different. It mainly regulates the channels of calcium ions and potassium ions, which not only inhibits the absorption of sodium ions, but also increases the content of potassium ions in the body to keep them in balance, thereby achieving the effect of lowering blood pressure and protecting blood vessels.

Not only can it lower blood pressure quickly, but also control blood pressure stably for a long time, and its side effects are much smaller than those of common antihypertensive drugs.

Therefore, it will not only replace the antihypertensive drugs such as Huoluoxi and other antihypertensive drugs, but also sartan antihypertensive drugs, and become the first choice for all hypertensive patients.

There are 1.3 billion hypertensive patients in the world, and the market prospect is very broad. Antihypertensive drugs are also a battleground for major pharmaceutical companies. Every year, countless pharmaceutical companies are developing new antihypertensive drugs.

Weikang believes that this new antihypertensive drug will once again cause shocks in the global antihypertensive drug market after it is launched on the market.

As long as the price is not particularly high, after a few years, it will inevitably sweep the global market.

It is impossible to directly occupy all the markets, because antihypertensive drugs are a relatively old and mature market, and many antihypertensive drugs have a history of more than ten or even twenty or thirty years.

Antihypertensive drugs are drugs that need to be taken for a long time and safety is paramount. Most hypertensive patients generally choose safer and more reliable drugs that have experienced long-term market tests.

However, it is not a problem to grab a piece of market share and gradually erode the market of other pharmaceutical companies.

After reading this antihypertensive drug, he turned his attention to another special antithrombotic drug.

Thrombus is mainly composed of insoluble fibrin, deposited platelets, clogged red blood cells and white blood cells.

It can cause a series of symptoms such as varicose veins, swelling of the lower limbs, dyspnea, etc. In severe cases, it can also cause cerebral thrombosis, which can cause sudden death of a healthy ordinary person at any time.

Every year in the news, there are many news of sudden death caused by continuous overtime work, which is simply endless.

Some people have vascular disease caused by high blood pressure, high blood sugar, high blood lipids, etc., which lead to thrombosis.

There are also some people who have injured the blood vessel wall after surgery.

Either way, they will take antithrombotic drugs.

This is a common disease of the elderly and people with three highs.

On average, 20 million people in the world are killed by cardiovascular and cerebrovascular diseases every year, and one third of them die from stroke (stroke). China is a country with a high incidence of stroke, and the number of deaths ranks first in the world. There are 1.5 million people.

That's why sales of antithrombotic drugs are so high.

There are so many pharmaceutical companies that produce antithrombotic drugs in the world. A giant like Pfizer can sell billions of dollars every year, and some small pharmaceutical companies can also sell tens of millions of dollars for antithrombotic drugs.

Moreover, antithrombotic drugs are also a very mature and ancient market, with a wide variety of drugs and many choices for patients.

However, when most people choose drugs, they still try to choose products of big brands, which are guaranteed to be effective.

This is a market worth tens of billions of dollars, with huge profits, blockbuster drugs emerging one after another, and many giants fighting fiercely.

The king of drugs in the antithrombotic field is apixaban developed by Bristol-Myers Squibb, an intravenous anticoagulant drug whose global sales have exceeded US$10 billion within seven years of its launch.

Common antithrombotic drugs are mainly divided into anticoagulant drugs, antiplatelet aggregation drugs, and thrombolytic drugs. The three drugs are different, each has a different mechanism of action, and is used for different diseases.

Anticoagulants are often used to prevent venous thrombosis, and antiplatelet drugs are often used to prevent arterial thrombosis.

The effect of thrombolytic drugs is faster than anticoagulant drugs, but the risk of bleeding is greater, so they often need to be supervised by doctors in hospitals.

The antithrombotic drug in Weikang's hands mainly prevents platelet aggregation and dissolves fibrin at the same time. It is very effective in preventing arterial thrombosis and dissolving thrombus.

Extremely dangerous cardiovascular and cerebrovascular diseases such as cerebral apoplexy (stroke) and sudden myocardial infarction are all caused by arterial embolism, which are applicable diseases of this new drug.

"It's great! These are two god-level drugs, and I can't wait to see the clinical effect!"

"If the clinical effect is really that good, it will definitely be two ace drugs with annual sales exceeding tens of billions of dollars."

Wei Kang's eyes lit up, as if he had seen two glittering golden medicine kings waving to him.

He quickly distributed these seven prescriptions to the employees of his laboratory to start a series of follow-up developments.

Since antihypertensive drugs and antithrombotic drugs are taken for a long time, the clinical requirements are very strict. It is necessary to start from the first clinical phase, and the number of people in each phase should be as large as possible.

Even after it goes on the market, it will continue to conduct Phase IV clinical trials to monitor the side effects and long-term effects of patients taking the medicine at any time.

The previous anti-cancer drugs and AD specific drugs, because they are breakthrough innovative drugs, all go through the green and fast application channel, and it only takes a few months from clinical to market.

However, these two cardiovascular and cerebrovascular drugs are not breakthrough innovative drugs, so they cannot go through the fast-track approval channel.

In short, this is a long and costly long-term process.

Wei Kang finally realized the painstaking and lengthy process of traditional drug research and development.

Fortunately, several other drugs are not so troublesome.

Hair removal cream belongs to common cosmetics, and it is enough to do a phase II clinical trial to prove the effect.

Quscar ointment is an over-the-counter drug for external use, the clinical trial requirements are not strict, and the marketing process is relatively simple.

Of course, it can also be made into skin care products by diluting it. It is definitely a face cream that claims to be able to remove scars like La Mer.

Anti-allergic drugs are prescription drugs, and they need to undergo clinical phase II and III trials. The process should be very fast, and they can also be made into anti-allergic skin care products.

As for pesticides and veterinary drugs, they only need to test their safety and do animal testing. Compared with drugs for human use, the approval process is simple and quick.

I believe that within a few months, Sanqing will have several new drugs on the market.